FDA Expands Approval for Eli Lilly Therapy in Untreated Leukemia Patients

기사 요약

FDA approves Eli Lilly's Jaypirca for adults with untreated CLL/SLL without 17p deletion based on Phase 3 BRUIN CLL-313 trial results.